Junshi Biosciences Announces Final Analysis Results of the Phase 3 NEOTORCH Study at ESMO Congress 2026
Perioperative toripalimab plus chemotherapy demonstrated significant and durable improvements in EFS and OS in patients with resectable stage II-III NSCLC.
Covered in this story
Call it yourself
No calls on $III yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Information Services Group Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.